Intellia Therapeutics Inc - Asset Resilience Ratio
Intellia Therapeutics Inc (NTLA) has an Asset Resilience Ratio of 34.96% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Intellia Therapeutics Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Intellia Therapeutics Inc's Asset Resilience Ratio has changed over time. See NTLA net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Intellia Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Intellia Therapeutics Inc (NTLA) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $294.42 Million | 34.96% |
| Total Liquid Assets | $294.42 Million | 34.96% |
Asset Resilience Insights
- Very High Liquidity: Intellia Therapeutics Inc maintains exceptional liquid asset reserves at 34.96% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Intellia Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Intellia Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Intellia Therapeutics Inc (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Intellia Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 34.96% | $294.42 Million | $842.13 Million | +0.34pp |
| 2024-12-31 | 34.62% | $412.33 Million | $1.19 Billion | -18.07pp |
| 2023-12-31 | 52.69% | $685.48 Million | $1.30 Billion | +8.67pp |
| 2022-12-31 | 44.02% | $669.12 Million | $1.52 Billion | -4.29pp |
| 2021-12-31 | 48.30% | $625.28 Million | $1.29 Billion | -16.36pp |
| 2020-12-31 | 64.67% | $437.35 Million | $676.32 Million | -1.89pp |
| 2019-12-31 | 66.56% | $222.50 Million | $334.28 Million | -6.92pp |
| 2018-12-31 | 73.48% | $255.20 Million | $347.31 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $376.24 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $298.97 Million | -- |
About Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agree… Read more